These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 37400283

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D.
    Vaccine; 1999 Aug 06; 17(23-24):3109-15. PubMed ID: 10462247
    [Abstract] [Full Text] [Related]

  • 4. A Novel Shigella O-Polysaccharide-IpaB Conjugate Vaccine Elicits Robust Antibody Responses and Confers Protection against Multiple Shigella Serotypes.
    Desalegn G, Kapoor N, Pill-Pepe L, Bautista L, Yin L, Ndungo E, Oaks EV, Fairman J, Pasetti MF.
    mSphere; 2023 Jun 22; 8(3):e0001923. PubMed ID: 37017547
    [Abstract] [Full Text] [Related]

  • 5. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.
    Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R, Israel Shigella Study Group.
    Pediatr Infect Dis J; 2003 Aug 22; 22(8):701-6. PubMed ID: 12913770
    [Abstract] [Full Text] [Related]

  • 6. Stable Chromosomal Expression of Shigella flexneri 2a and 3a O-Antigens in the Live Salmonella Oral Vaccine Vector Ty21a.
    Dharmasena MN, Osorio M, Takeda K, Stibitz S, Kopecko DJ.
    Clin Vaccine Immunol; 2017 Dec 22; 24(12):. PubMed ID: 29046309
    [Abstract] [Full Text] [Related]

  • 7. Outer Membrane Vesicles Derived from Salmonella enterica Serotype Typhimurium Can Deliver Shigella flexneri 2a O-Polysaccharide Antigen To Prevent Shigella flexneri 2a Infection in Mice.
    Tian H, Li B, Xu T, Yu H, Chen J, Yu H, Li S, Zeng L, Huang X, Liu Q.
    Appl Environ Microbiol; 2021 Sep 10; 87(19):e0096821. PubMed ID: 34319809
    [Abstract] [Full Text] [Related]

  • 8. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
    Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R.
    Infect Immun; 2001 Mar 10; 69(3):1351-7. PubMed ID: 11179298
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection.
    Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti PJ, Mulard LA.
    J Immunol; 2009 Feb 15; 182(4):2241-7. PubMed ID: 19201878
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection.
    Talaat KR, Alaimo C, Martin P, Bourgeois AL, Dreyer AM, Kaminski RW, Porter CK, Chakraborty S, Clarkson KA, Brubaker J, Elwood D, Frölich R, DeNearing B, Weerts H, Feijoo BL, Halpern J, Sack D, Riddle MS, Fonck VG.
    EBioMedicine; 2021 Apr 15; 66():103310. PubMed ID: 33862589
    [Abstract] [Full Text] [Related]

  • 13. Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice.
    Farzam N, Ramon-Saraf R, Banet-Levi Y, Lerner-Geva L, Ashkenazi S, Kubler-Kielb J, Vinogradov E, Robbins JB, Schneerson R.
    Vaccine; 2017 Sep 05; 35(37):4990-4996. PubMed ID: 28797729
    [Abstract] [Full Text] [Related]

  • 14. Rationalizing the design of a broad coverage Shigella vaccine based on evaluation of immunological cross-reactivity among S. flexneri serotypes.
    Citiulo F, Necchi F, Mancini F, Rossi O, Aruta MG, Gasperini G, Alfini R, Rondini S, Micoli F, Rappuoli R, Saul A, Martin LB.
    PLoS Negl Trop Dis; 2021 Oct 05; 15(10):e0009826. PubMed ID: 34644291
    [Abstract] [Full Text] [Related]

  • 15. Shigella-Specific Immune Profiles Induced after Parenteral Immunization or Oral Challenge with Either Shigella flexneri 2a or Shigella sonnei.
    Clarkson KA, Porter CK, Talaat KR, Frenck RW, Alaimo C, Martin P, Bourgeois AL, Kaminski RW.
    mSphere; 2021 Aug 25; 6(4):e0012221. PubMed ID: 34259559
    [Abstract] [Full Text] [Related]

  • 16. Determinants of immune responses predictive of protection against shigellosis in an endemic zone: a systems analysis of antibody profiles and function.
    Bernshtein B, Kelly M, Cizmeci D, Zhiteneva JA, Macvicar R, Kamruzzaman M, Bhuiyan TR, Chowdhury F, Khan AI, Qadri F, Charles RC, Xu P, Kováč P, Clarkson KA, Kaminski RW, Alter G, Ryan ET.
    Lancet Microbe; 2024 Oct 25; 5(10):100889. PubMed ID: 39116906
    [Abstract] [Full Text] [Related]

  • 17. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
    Cohen D, Ashkenazi S, Schneerson R, Farzam N, Bialik A, Meron-Sudai S, Asato V, Goren S, Baran TZ, Muhsen K, Gilbert PB, MacLennan CA.
    Clin Microbiol Infect; 2023 Mar 25; 29(3):366-371. PubMed ID: 36243351
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon ML, Bialik A, Goren S, Asato V, Ariel-Cohen O, Reizis A, Dorman A, Hoitink CWG, Westdijk J, Ashkenazi S, Sansonetti P, Mulard LA, Phalipon A.
    Lancet Infect Dis; 2021 Apr 25; 21(4):546-558. PubMed ID: 33186516
    [Abstract] [Full Text] [Related]

  • 19. Shigella-specific antibodies in the first year of life among Zambian infants: A longitudinal cohort study.
    Chisenga CC, Bosomprah S, Simuyandi M, Mwila-Kazimbaya K, Chilyabanyama ON, Laban NM, Bialik A, Asato V, Meron-Sudai S, Frankel G, Cohen D, Chilengi R.
    PLoS One; 2021 Apr 25; 16(5):e0252222. PubMed ID: 34043697
    [Abstract] [Full Text] [Related]

  • 20. A broadly immunogenic polyvalent Shigella multiepitope fusion antigen protein protects against Shigella sonnei and Shigella flexneri lethal pulmonary challenges in mice.
    Li S, Anvari S, Ptacek G, Upadhyay I, Kaminski RW, Sack DA, Zhang W.
    Infect Immun; 2023 Nov 16; 91(11):e0031623. PubMed ID: 37795982
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.